Stryker, a medical technology company, has announced a definitive agreement to acquire Inari Medical for $80 per share in cash, valuing the transaction at approximately $4.9 billion. Inari, established in 2011, specializes in mechanical thrombectomy solutions for venous thromboembolism (VTE), a condition that affects up to 900,000 people annually in the U.S. The acquisition aims to complement Stryker’s Neurovascular business by adding Inari’s innovative peripheral vascular products to its portfolio, further enhancing its ability to address unmet clinical needs in endovascular procedures. The Board of Directors of both companies has unanimously approved the agreement. Pending regulatory approvals and other customary conditions, the transaction is expected to close by the end of the first quarter of 2025.
Inari Medical has gained recognition for its purpose-built tools that offer solutions for VTE clot removal without thrombolytic drugs, significantly improving patient outcomes. The acquisition will allow Stryker to leverage its infrastructure to accelerate the development and distribution of these life-saving technologies. Kevin Lobo, Chair and CEO of Stryker said, “The acquisition of Inari expands Stryker's portfolio to provide life-saving solutions to patients who suffer from peripheral vascular diseases. These innovations elevate the standard of care for venous thromboembolism patients and will accelerate Stryker’s impact in endovascular procedures.” Drew Hykes, Chief Executive Officer, Inari added “With Stryker’s capabilities and global infrastructure, we will be even better positioned to accelerate the development of innovative new solutions and expand our footprint.”
